Compare FRPH & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | CUVL |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Real Estate | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 374.2M |
| IPO Year | 1995 | N/A |
| Metric | FRPH | CUVL |
|---|---|---|
| Price | $22.14 | $7.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.7K | 6.5K |
| Earning Date | 04-10-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,846,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $20.53 | $6.20 |
| 52 Week High | $26.32 | $8.20 |
| Indicator | FRPH | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 58.90 |
| Support Level | $21.92 | $6.45 |
| Resistance Level | $24.57 | N/A |
| Average True Range (ATR) | 0.54 | 0.29 |
| MACD | 0.15 | 0.10 |
| Stochastic Oscillator | 66.09 | 66.66 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.